According to the company, the SV70 allows clinicians to switch between non-invasive ventilation and integrated high-flow oxygen therapy. The system is currently available in the U.S., with demonstrations planned at the American Association for Respiratory Care Congress in New Orleans this November.
Mindray said the SV70 was designed specifically to help address Philips Respironics’ discontinuation of its V60 and V60 Plus, following multiple device corrections and recalls during recent years. Philips has said it has largely completed remediation efforts and would continue to service the ventilators through December 2029, while parts are still available.
With its turbine-driven, single-limb platform, the SV70 is compatible with the same accessories used with the Philips V60 while sharing the same touchscreen interface as Mindray’s SV900 and SV700, as the company targets healthcare providers seeking to replace their entire ventilator stock.
“The SV70 was built with a clear purpose: to give respiratory departments a platform they can standardize on for the long term,” said Wayne Quinn, president of Mindray North America. “This is not a stopgap solution; It is a commitment to empowering clinicians to deliver exceptional care, every time.”
China-based Mindray, with its U.S. headquarters in New Jersey, announced that it would enter the stateside ventilator market this past March. That followed up on an expansion of its partnership with Medtronic, which broadened its patient monitoring pact in hospitals to include ambulatory surgical centers.
Medtronic officially left the market in early 2024, after exploring plans to spin off its patient monitoring and respiratory interventions portfolios into a standalone company. During the COVID pandemic, the company took major strides to boost the production of its Puritan Bennett ventilators and other systems.
